Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2007 1
2008 1
2011 2
2012 4
2013 1
2014 1
2015 1
2016 2
2017 1
2020 1
2021 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Hereditary ovarian cancer in Poland.
Menkiszak J, Gronwald J, Górski B, Jakubowska A, Huzarski T, Byrski T, Foszczyńska-Kłoda M, Haus O, Janiszewska H, Perkowska M, Brozek I, Grzybowska E, Zientek H, Góźdź S, Kozak-Klonowska B, Urbański K, Miturski R, Kowalczyk J, Pluzańska A, Niepsuj S, Koc J, Szwiec M, Drosik K, Mackiewicz A, Lamperska K, Strózyk E, Godlewski D, Stawicka M, Waśko B, Bebenek M, Rozmiarek A, Rzepka-Górska I, Narod SA, Lubiński J. Menkiszak J, et al. Among authors: foszczynska kloda m. Int J Cancer. 2003 Oct 10;106(6):942-5. doi: 10.1002/ijc.11338. Int J Cancer. 2003. PMID: 12918074
Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study.
Durbajło A, Świeżyński M, Ziemba B, Starzyczny-Słota D, Samborska-Plewicka M, Cencelewicz-Lesikow A, Chrzanowska-Kapica A, Dobrzyńska-Rutkowska A, Drab-Mazur I, Kulma-Kreft M, Sikora-Skrabaka M, Matuszewska E, Foszczyńska-Kłoda M, Lewandowski T, Słomian G, Ostrowska-Cichocka K, Chmielowska E, Wiśniowski R, Twardosz A, Wierzbicka K, Rumianowski L, Wyrwicz L. Durbajło A, et al. Among authors: foszczynska kloda m. Cancers (Basel). 2024 May 24;16(11):1992. doi: 10.3390/cancers16111992. Cancers (Basel). 2024. PMID: 38893113 Free PMC article.
Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil.
Malik M, Radecka B, Gełej M, Jackowska A, Filipczyk-Cisarż E, Żurowska M, Hetman K, Foszczyńska-Kłoda M, Kania-Zembaczyńska B, Mańka D, Orlikowska M, Bodnar L. Malik M, et al. Among authors: foszczynska kloda m. Biomedicines. 2024 Sep 11;12(9):2076. doi: 10.3390/biomedicines12092076. Biomedicines. 2024. PMID: 39335589 Free PMC article.
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil.
Malik M, Michalak M, Radecka B, Gełej M, Jackowska A, Filipczyk-Cisarż E, Hetman K, Foszczyńska-Kłoda M, Kania-Zembaczyńska B, Mańka D, Orlikowska M, Rogowska-Droś H, Bodnar L. Malik M, et al. Among authors: foszczynska kloda m. J Clin Med. 2021 Oct 30;10(21):5107. doi: 10.3390/jcm10215107. J Clin Med. 2021. PMID: 34768626 Free PMC article.
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.
Duchnowska R, Jarząb M, Żebracka-Gala J, Matkowski R, Kowalczyk A, Radecka B, Kowalska M, Pfeifer A, Foszczyńska-Kłoda M, Musolino A, Czartoryska-Arłukowicz B, Litwiniuk M, Surus-Hyla A, Szabłowska-Siwik S, Karczmarek-Borowska B, Dębska-Szmich S, Głodek-Sutek B, Sosińska-Mielcarek K, Chmielowska E, Kalinka-Warzocha E, Olszewski WP, Patera J, Żawrocki A, Pliszka A, Tyszkiewicz T, Rusinek D, Oczko-Wojciechowska M, Jassem J, Biernat W; Polish Brain Metastasis Consortium. Duchnowska R, et al. Among authors: foszczynska kloda m. Clin Breast Cancer. 2017 Apr;17(2):e65-e75. doi: 10.1016/j.clbc.2016.08.008. Epub 2016 Sep 8. Clin Breast Cancer. 2017. PMID: 27692773
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG). Duchnowska R, et al. Among authors: foszczynska kloda m. Oncotarget. 2016 Jan 5;7(1):550-64. doi: 10.18632/oncotarget.6375. Oncotarget. 2016. PMID: 26623720 Free PMC article.
19 results